EGFR and neoplasm: Despite other studies showing that cancers with mutated EGFR [38, 39] treated with erlotinib leads to increased tumor killing by NK cells [9], our studies do not show a reliable increase in NK cell killing by erlotinib, especially when compared to the NK cell killing induced by cSNX1.3.